bioRxiv 预印本· chen, y., Haffner, C., Chellakkan Selvanesan, B., Wu, R., Ballaro, R., Vilchis Celis, A., Zuo, M., Patterson, L., Adofo, M., Vykoukal, J., Leon-Letelier, R., Dou, R., Park, S., Cai, Y., Rodriguez-Perera, D., Irajizad, E., McAllister, F., Kim, M., Koay, E., Wolpin, B., Hsiao, F. C., Dennison, J., Katayama, H., Bernard Pagan, V., Maitra, A., Hanash, S., Fahrmann, J. ·· 15 小时前AI 评分22
KRAS驱动MFSD2A介导溶血磷脂酰胆碱清除增强，促进胰腺导管腺癌生存与进展
KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adenocarcinoma
AI 导读
bioRxiv预印本研究显示，胰腺导管腺癌（PDAC）中致癌KRAS上调MFSD2A，增强细胞对胞外不饱和LysoPC的摄取以维持促生长信号。MFSD2A缺失可抑制AKT信号、促进凋亡并在体内抑制肿瘤生长；老药edelfosine靶向KRAS-MFSD2A-LysoPC轴在体外表现出抗癌效应。
来源：bioRxiv 预印本 · biorxiv.org